FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Maggiore Christopher D. 2. Issuer Name and Ticker or Trading Symbol Zivo Bioscience, Inc. [ ZIVO ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)
4788 NOBLES POND DR. NW		 3. Date of Earliest Transaction (MM/DD/YYYY)
9/14/2022
(Street)
CANTON, OH 44718
(City)        (State)        (Zip)
 4. If Amendment, Date Original Filed (MM/DD/YYYY)
9/19/2022 
 6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  9/14/2022    P    5200  A $3.5281 (1) 721282 (3) D   
Common Stock  9/14/2022    P    2000  A $3.5507 (2) 723282  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.45 to $3.7257 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
(2)  The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.435 to $3.93 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
(3)  The total number of shares reported in Column 5 differs from amounts previously reported, which incorrectly included shares held in the estate of Robert S. McLain and in a related trust, as to which the reporting person was appointed a co-trustee in 2014. Although the reporting person has shared power to vote or to direct the vote, and shared power to dispose or to direct the disposition of, the shares held in the estate and in the trust, the reporting person has no direct or indirect pecuniary interest in such shares.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Maggiore Christopher D.
4788 NOBLES POND DR. NW
CANTON, OH 44718		 X



Signatures
/s/ Christopher D. Maggiore 2/14/2023
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Zivo Bioscience (NASDAQ:ZIVO)
Historical Stock Chart
From May 2023 to Jun 2023 Click Here for more Zivo Bioscience Charts.
Zivo Bioscience (NASDAQ:ZIVO)
Historical Stock Chart
From Jun 2022 to Jun 2023 Click Here for more Zivo Bioscience Charts.